Market Cap
$872.6M
SANA
Sana Biotechnology, Inc.
$2.87 ▼ -0.69%
Prev close $2.89Market cap$872.6M
ConsensusStrong Buy
12-mo target$8.43 (+193.7%)
▲ Bullish
Analyst conviction 9/10
17 New Institutional Positions20 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SANA right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (87%)
Inst. Holders
50 funds
Inst. Value
$523.8M
Inst. Activity
17 buys / 20 sells
Social Sentiment
36° Cool
SEC Reports
7
Press Releases
3
Price chart 30d -26.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: SANA — 66.7% short (1.0M / 1.5M)
Short: 1,015,097 | Exempt: 14,116 | TRF Vol: 1,521,935 | Short Ratio: 66.7% | Off-exchange volume (d
Aug 27, 2026 Insider
PATEL DHAVALKUMAR DHIRAJLAL surrendered for taxes 41,158 shares
EVP, Chief Scientific Officer @ $4.11 ($169.2K)
Aug 26, 2026 Insider
Aug 11, 2026 SEC PATEL DHAVALKUMAR DHIRAJLAL acquired via exercise 125,000 shares
EVP, Chief Scientific Officer
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), a narrower loss vs $93.8M ($0.39/share) in Q2
8-K — Impact 5/10
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M lo
PRESS-RELEASE — Impact 4/10
Jul 6, 2026 Insider
Bishop Hans Edgar was granted 6,297 shares
Director
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
18,750,000 shares ($65.4M)
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — ADD
5,748,454 shares ($20.1M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
87% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Apr 14, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Aug 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Jul 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Jun 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| May 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% | |
| Feb 1, 2026 | 6 | 7 | 2 | 0 | 0 | 87% |
Price targets
Where 7 covering analysts think SANA trades over the next 12 months.
$8.43 +193.7% upside Strong Buy
Current$2.87 Low$6.00 Median$7.00 High$12.00 7 analysts
$6.00$12.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +40.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
36°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 4.4/10.Plus 3 press releases.
NEUTRAL8-K5/10
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), a narrower loss vs $93.8M
Aug 11, 2026
NEUTRALPRESS-RELEASE4/10
Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than th
Aug 10, 2026
BEARISHPRESS-RELEASE6/10
Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21
May 11, 2026
NEUTRAL8-K4/10
Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than t
May 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: SANA — 66.7% short (1.0M / 1.5M)
Short: 1,015,097 | Exempt: 14,116 | TRF Vol: 1,521,935 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: SANA — 58.5% short (0.8M / 1.4M)
Short: 791,990 | Exempt: 0 | TRF Vol: 1,352,790 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: SANA — 62.9% short (0.8M / 1.3M)
Short: 799,395 | Exempt: 151 | TRF Vol: 1,271,239 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: SANA — 65.8% short (1.1M / 1.7M)
Short: 1,124,910 | Exempt: 100 | TRF Vol: 1,710,420 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: SANA — 77.1% short (2.9M / 3.7M)
Short: 2,869,502 | Exempt: 1,129 | TRF Vol: 3,719,736 | Short Ratio: 77.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.13 | $-0.19–$-0.10 | 11.0% | -9.8% | 2↑ 1↓ | $0.0B | 4 |
| Next Q | $-0.16 | $-0.20–$-0.11 | -1.7% | +8.2% | 2↑ 2↓ | $0.0B | 4 |
| Current FY | $-0.59 | $-0.71–$-0.48 | 11.8% | -2.0% | 2↑ 2↓ | $0.0B | 4 |
| Next FY | $-0.56 | $-0.74–$-0.42 | 6.1% | -6.3% | 1↑ 1↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.134 | — |
| 7d ago | $-0.122 | -0.012 |
| 30d ago | $-0.122 | -0.012 |
| 60d ago | $-0.123 | -0.010 |
| 90d ago | $-0.123 | -0.010 |
Institutional ownership
Which big funds own SANA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $523.8M total value (150,133,867 shares) as of 2026-Q2. Top holders: FMR, RA, BlackRock,. Net selling activity: 20 institutions trimmed/exited vs 17 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 37,429,515 | $130.6M | 24.9% | — |
| RA CAPITAL MANAGEMENT, L.P. | 18,750,000 | $65.4M | 12.5% | NEW |
| BlackRock, Inc. | 16,675,173 | $58.2M | 11.1% | — |
| STATE STREET CORP | 11,203,134 | $39.1M | 7.5% | ADD +30.8% |
| CANADA PENSION PLAN INVESTMENT BOARD | 10,218,400 | $35.7M | 6.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,375,421 | $29.2M | 5.6% | — |
| BANK OF AMERICA CORP /DE/ | 5,748,454 | $20.1M | 3.8% | ADD +95.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 4,677,959 | $16.3M | 3.1% | — |
| Marex Group Ltd | 3,989,100 | $13.9M | 2.7% | — |
| MARSHALL WACE, LLP | 2,931,436 | $10.2M | 2.0% | DOUBLED +341.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 18,750,000 | — | $65.4M |
| BANK OF AMERICA CORP /DE/ | ADD | 2,946,861 | 5,748,454 | +95.1% | $20.1M |
| MARSHALL WACE, LLP | DOUBLED | 664,457 | 2,931,436 | +341.2% | $10.2M |
| GOLDMAN SACHS GROUP INC | TRIM | 3,181,115 | 2,367,935 | -25.6% | $8.3M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 1,591,030 | 653,503 | -58.9% | $2.3M |
| CITIGROUP INC | DOUBLED | 60,391 | 272,524 | +351.3% | $951.1K |
| Rafferty Asset Management, LLC | TRIM | 353,582 | 196,731 | -44.4% | $686.6K |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 74,827 | 193,283 | +158.3% | $674.6K |
| Russell Investments Group, Ltd. | DOUBLED | 11,066 | 174,787 | +1479.5% | $610.0K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 75,682 | 173,546 | +129.3% | $605.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 26 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | PATEL DHAVALKUMAR DHIRAJLAL | EVP, Chief Scientific Officer | TAX W/H | 41,158 | $4.11 | $169.2K |
| Aug 26, 2026 | PATEL DHAVALKUMAR DHIRAJLAL | EVP, Chief Scientific Officer | EXERCISE | 125,000 | — | — |
| Jul 6, 2026 | Bishop Hans Edgar | Director | AWARD | 6,297 | — | — |
| Jun 4, 2026 | NELSEN ROBERT | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Bishop Hans Edgar | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Bilenker Joshua H. | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | REICIN ALISE | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Mulligan Richard | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Seitz Michelle | Director | AWARD | 90,000 | — | — |
| Jun 4, 2026 | Rosiello Robert L. | Director | AWARD | 90,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SANA.
Shares short
41,374,811
Settlement Sep 15, 2026
Change vs prior
-0.5%
Semi-monthly cycle
Days to cover
12.2
At avg daily volume
Of shares outstanding
≈13.8%
Estimate — not % of float
All SANA filing & press-release reports (10)
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportAug 10, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportMay 11, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportApr 24, 2026
- 8-K reportApr 13, 2026
- PRESS-RELEASE reportApr 13, 2026
- PRESS-RELEASE reportMar 13, 2026
- PRESS-RELEASE reportMar 3, 2026